Characteristic of the invention includes compound IA, IB, IC or ID of place's what amorphous form or the solid composite of its pharmaceutically acceptable salt in what. In one embodiment, compound IA, IB, IC or ID or its pharmaceutically acceptable salt are prepared in the amorphous solid dispersion comprising pharmaceutically acceptable hydrophilic polymer and preferred pharmaceutically acceptable surfactant.本發明的特徵在於包含處於無定形形式的化合物IA、IB、IC或ID、或其藥學上可接受的鹽的固體組合物。在一個實施方案中，將化合物IA、IB、IC或ID、或其藥學上可接受的鹽配製在包含藥學上可接受的親水性聚合物和優選的藥學上可接受的表面活性劑的無定形固體分散體中。
